ETF Holdings Breakdown of XENE

Stock NameXenon Pharmaceuticals Inc
TickerXENE(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINCA98420N1050

News associated with XENE

Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) saw unusually large options trading on Wednesday. Traders bought 4,063 put options on the company. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Hedge Funds Weigh In On Xenon Pharmaceuticals Several large investors have recently modified their holdings of […] - 2025-06-26 06:00:54
Comparing Xenon Pharmaceuticals (NASDAQ:XENE) & Inhibitor Therapeutics (OTCMKTS:INTI)
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and Inhibitor Therapeutics (OTCMKTS:INTI – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation. Insider & Institutional Ownership 95.4% of Xenon Pharmaceuticals […] - 2025-06-04 06:06:45
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of “Buy” from Brokerages
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) have earned an average recommendation of “Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. Twelve equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have updated their coverage […] - 2025-05-26 07:40:52
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday. Other equities research analysts have also issued reports about the stock. Evercore ISI assumed coverage on shares of Xenon Pharmaceuticals in a research note […] - 2025-05-21 08:12:51
D. E. Shaw & Co. Inc. Sells 117,919 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
D. E. Shaw & Co. Inc. lowered its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 57.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,973 shares of the biopharmaceutical company’s stock after selling 117,919 shares during the quarter. D. […] - 2025-05-19 08:12:55
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $47.00 Price Target at Wells Fargo & Company
Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its target price cut by Wells Fargo & Company from $50.00 to $47.00 in a research report report published on Tuesday, Marketbeat.com reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Several other research analysts also recently issued reports on the company. William Blair reaffirmed […] - 2025-05-16 06:05:00
Needham & Company LLC Cuts Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00
Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its price target trimmed by Needham & Company LLC from $60.00 to $55.00 in a research report report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on XENE. The Goldman Sachs […] - 2025-05-16 06:04:59
Chardan Capital Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
Chardan Capital reaffirmed their buy rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $55.00 price objective on the biopharmaceutical company’s stock. Several other research firms also recently commented on XENE. Royal Bank of Canada reiterated an “outperform” rating on shares of […] - 2025-05-16 06:04:56
Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock investors purchased 4,063 put options on the stock. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Analysts Set New Price Targets Several research analysts recently issued reports […] - 2025-05-15 07:31:06
Royal Bank of Canada Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target reduced by equities research analysts at Royal Bank of Canada from $58.00 to $55.00 in a research report issued to clients and investors on Tuesday, MarketBeat reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target […] - 2025-05-15 05:48:49
HC Wainwright Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $53.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 78.21% from the stock’s previous close. Other research analysts […] - 2025-05-15 05:48:48
StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to “Hold”
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Tuesday. A number of other equities research analysts have also recently commented on XENE. Royal Bank of Canada cut their target price on Xenon Pharmaceuticals from $58.00 to […] - 2025-05-15 05:16:49
Raymond James Financial Inc. Invests $797,000 in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Raymond James Financial Inc. purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 20,331 shares of the biopharmaceutical company’s stock, valued at approximately $797,000. A number of […] - 2025-05-07 07:38:48
William Blair Reiterates Outperform Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at William Blair in a note issued to investors on Monday,RTT News reports. XENE has been the topic of several other reports. The Goldman Sachs Group dropped their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set […] - 2025-05-07 05:22:49
Xenon Pharmaceuticals (NASDAQ:XENE) Cut to “Sell” at StockNews.com
StockNews.com downgraded shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) from a hold rating to a sell rating in a report released on Friday morning. XENE has been the topic of several other reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a […] - 2025-05-05 05:28:52
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors acquired 4,063 put options on the company. This is an increase of approximately 2,362% compared to the average daily volume of 165 put options. Xenon Pharmaceuticals Stock Performance XENE opened at $38.20 on Thursday. The […] - 2025-05-01 07:46:54
Guggenheim Capital LLC Decreases Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Guggenheim Capital LLC lowered its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 41.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,177 shares of the biopharmaceutical company’s stock after selling 4,452 shares during the quarter. Guggenheim Capital LLC’s holdings in […] - 2025-04-29 08:30:55
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $56.78 Consensus PT from Analysts
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has been given a consensus recommendation of “Buy” by the ten analysts that are presently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock […] - 2025-04-29 06:10:55
Invesco Ltd. Cuts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Invesco Ltd. cut its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 2.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,554 shares of the biopharmaceutical company’s stock after selling 6,268 shares during the quarter. […] - 2025-04-24 08:00:53
Traders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading on Wednesday. Traders acquired 4,063 put options on the company. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Wall Street Analyst Weigh In A number of analysts have commented on the […] - 2025-04-17 07:41:09
Xenon Pharmaceuticals (NASDAQ:XENE) Rating Lowered to Sell at StockNews.com
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Wednesday. Several other equities research analysts have also recently commented on XENE. William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, […] - 2025-04-16 06:10:56
Trexquant Investment LP Has $447,000 Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Trexquant Investment LP trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 32.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,397 shares of the biopharmaceutical company’s stock after selling 5,510 shares during the period. Trexquant […] - 2025-04-13 08:31:04
Orion Portfolio Solutions LLC Sells 1,067 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Orion Portfolio Solutions LLC lowered its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 7.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,436 shares of the biopharmaceutical company’s stock after selling 1,067 shares during the period. Orion […] - 2025-04-08 07:58:59
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Prudential Financial Inc.
Prudential Financial Inc. increased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 177.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 39,000 shares of the biopharmaceutical company’s stock after buying an additional 24,956 shares during the quarter. Prudential Financial Inc.’s holdings in Xenon Pharmaceuticals were worth $1,529,000 at the end of […] - 2025-04-06 08:30:51
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $57.38 Average Target Price from Brokerages
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) have been given an average rating of “Buy” by the nine analysts that are currently covering the firm, MarketBeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have updated their coverage […] - 2025-04-04 06:05:07
Natixis Advisors LLC Sells 3,604 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Natixis Advisors LLC decreased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 13.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,554 shares of the biopharmaceutical company’s stock after selling 3,604 shares during the period. Natixis Advisors LLC’s […] - 2025-03-27 08:05:07
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of some unusual options trading on Wednesday. Stock investors acquired 4,063 put options on the company. This is an increase of 2,362% compared to the average volume of 165 put options. Xenon Pharmaceuticals Trading Down 0.7 % Shares of NASDAQ:XENE opened at $34.94 on […] - 2025-03-20 07:42:55
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $57.38 Consensus Price Target from Brokerages
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has earned an average rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued ratings on the stock […] - 2025-03-10 05:51:05
Stock Traders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Traders purchased 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the typical daily volume of 165 put options. Insider Activity In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold […] - 2025-03-06 07:51:35
Xenon Pharmaceuticals (NASDAQ:XENE) Earns Buy Rating from Analysts at Deutsche Bank Aktiengesellschaft
Equities research analysts at Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $67.00 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s target price would suggest […] - 2025-02-13 08:26:51

XENE institutional holdings

The following institutional investment holdings of XENE have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-26 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 44,215USD 1,423,723
2025-06-26 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 66,809USD 2,151,250
2025-06-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 38,291USD 1,232,970
2025-06-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 38,291USD 1,232,970
2025-06-26 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 3,196USD 102,911
Total =190,802 USD 6,143,824
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.